Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient's damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.
Frequently asked questions
What sector does PolTREG S.A. (PTG) operate in?
PolTREG S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PolTREG S.A. (PTG) current stock price?
As of the latest data, PolTREG S.A. stock price is PLN 26.90, with a previous close of PLN 26.90.
What is PolTREG S.A. (PTG) current market capitalization?
PolTREG S.A. market cap is approximately 146.06 million.
What is PolTREG S.A. (PTG) Earnings Per Share (EPS)?
The trailing EPS is -PLN 5.86, and the forward EPS is PLN 3.83.
What is PolTREG S.A. (PTG) EBITDA?
PolTREG S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.70 million.
Does PolTREG S.A. (PTG) pay dividends?
No. PolTREG S.A. does not pay a dividend.
What is PolTREG S.A. (PTG) beta (volatility) score?
PolTREG S.A. has a beta of 0.907, meaning its volatility is roughly in line with the market.
